“MEA-based Electrophysiological Evaluation – Cardiomyocyte Performance validation Service“
NEXEL offers a performance validation service for client-developed cardiomyocytes (including iPSC-derived cells) using the Multi-Electrode Array (MEA) platform. By applying 3–4 reference compounds, we assess the fundamental electrophysiological properties of cardiomyocytes and verify their susceptibility to arrhythmia induction.
With NEXEL’s MEA service, you can ensure the functional reliability of cardiomyocytes and obtain critical data for drug development and cardiac safety research.
Electrophysiological Evaluation of iPSC-derived Cardiomyocytes using Axion MEA
MEA-based Electrophysiological changes in cardiomyocytes induced by ion channel blockers
| Parameters | Measurements | Clinical Equivalence |
|---|---|---|
| FPD (Time) |
Cardiac relaxation time, K+/Ca2+ Arrhythmia risk |
QT Interval |
| Spike Amplitude (Strength) | Cardiomyocyte contractility, Na+ beating strength | QRS Complex / Na+ Current |
Only comprehensive analysis utilizing multiple parameters,
including Field Potential Duration and Spike Amplitude, yields accurate results.
Key Endpoints
FPD
Conduction
Propagation
Pacing
Response
